AMRA optimizes whole-body MRI protocols and automated image analysis for Facioscapulohumeral Muscular Dystrophy (FSHD) clinical trials — used in ReDUX: Fulcrum’s Phase 2b trial assessing the efficacy and safety of Losmapimod for treating individuals with FSHD.
Please watch the introduction video and learn more further down the page.
To better understand FSHD and develop effective therapeutics and diagnostics, researchers need objective methods that can capture disease variations between individuals and over time, and can accomodate and encourage any participant regardless of mobility.
Researchers need whole-body MRI and expert image analysis. Fortunately, AMRA delivers— providing researchers with precise muscle and fat measurements for the whole body, muscle groups and single muscles.
Whole-body MRI can capture FSHD heterogeneity and potentially provide important information about disease severity in correlation with functional outcomes.
Normal and End-stage muscles may remain nearly the same throughout the relatively short time span of a clinical trial, whereas Intermediate muscles may change substantially. By imaging the Intermediate muscles, and following them over time, researchers can detect small and large changes—potentially even before individuals start to experience difficulties or notice changes in muscle function.
AMRA’s whole-body MRI measurements often correlate to and act as a companion to functional tests, helping eliminate the subjectivity and limitations of current disease assessment methods.
AMRA Medical is committed to improving the lives of people living with FSHD—and we offer our support through our whole-body MRI-based research services. We have worked closely with the researchers at Fulcrum Therapeutics on their Losmapimod program—from their early proof of concept studies to the current Phase 2 program—and we are ready to help teams worldwide push their clinical programs forward.
To all teams researching neuromuscular disorders: AMRA can help you generate robust and compelling data with our MRI measurements, develop precise MRI biomarkers, and build a regulatory strategy that catalyzes success.